The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
In February, Catalent agreed to be acquired by Novo Holdings for $63.50 a share. Novo Holdings will then sell three Catalent ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
STAT reporters Helen Branswell and Allison DeAngelis give updates, respectively, on bird flu and radiopharmaceuticals.
Denmarks economic prospects are surging, with the government revising GDP growth forecasts upwards for 2024 and 2025, largely ...
Ozempic and other GLP-1 drugs have surged in popularity, dominating U.S. medication spending in 2023 for their effectiveness in managing diabetes and promoting weight loss. As demand grows, promising ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...